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Weight loss in cancer patients remains a major clinical problem
because it results in loss of independence and reduces the quality
and duration of life (Inagaki et al, 1974; Kern and Norton, 1988;
Ovesen et al, 1993). Randomized, placebo-controlled studies of
heterogeneous groups of cancer patients (mainly hormone-insensi-
tive tumours) have demonstrated that the administration of mege-
strol acetate can produce improvements in weight, appetite and
quality of life (Loprinzi et al, 1990; Feliu et al, 1991; Tchemedyian
et al, 1992). However, in similar studies in advanced gastro-
intestinal cancer patients, no significant gain in weight has been
documented (Schmoll et al, 1991; McMillan et al, 1994a).
The majority of gastrointestinal cancer patients with advanced
disease have evidence of an acute phase response (McMillan et al,
1994a; Goransson et al, 1996), and it has been reported that the
presence of such a response contributes to weight loss (Falconer et
al, 1994; McMillan et al, 1994b; Scott et al, 1996). Recent studies
have shown that concentrations of the proinflammatory cytokine
interleukin 6, the acute phase protein C-reactive protein and the
associated metabolic events can be moderated in such patients by
the administration of the non-steroidal anti-inflammatory agent
ibuprofen (McMillan et al, 1995; Preston et al, 1995; Wigmore et
al, 1995). We, therefore, hypothesized that down-regulating the
acute phase response using ibuprofen and stimulating the appetite
using megestrol acetate might be effective in reversing or halting
weight loss. The results of a small pilot study (McMillan et al,
1997) in weight-losing gastrointestinal cancer patients with an
acute phase protein response were encouraging and consistent
with this hypothesis because there appeared to be greater weight
gain compared with our published results using megestrol acetate
alone (McMillan et al, 1994a).
The objective of the current study was to establish in a random-
ized placebo-controlled double-blind trial whether the combination
of megestrol acetate (480 mg day—1) and ibuprofen (1200 mg day—1)
improved weight gain and quality of life in weight-losing gastro-
intestinal cancer patients compared with megestrol acetate alone.
MATERIALS AND METHODS
Patients (in two centres) with histologically proven, locally
advanced or metastatic gastrointestinal cancer, with more than 5%
weight loss who were receiving supportive care only, and had a life
expectancy of at least 2 months were considered eligible for inclu-
sion in the study. No patient complained of moderate or severe
dysphagia and none had an obvious functional obstruction to food
intake. No patient had grossly abnormal liver function tests. Other
exclusion criteria included poorly controlled hypertension, conges-
tive heart failure or a history of veno-occlusive disease.
Baseline measurements of height, weight, mid-upper arm
circumference, skinfold thicknesses, total body water, albumin and
C-reactive protein were carried out. Karnofsky performance
status, EuroQol and EORTC QLQ-C30 quality of life measures
were also recorded.
Patients included in the study were randomized to receive
megestrol acetate (160 mg three times daily)/ibuprofen (400 mg
three times daily) or megestrol acetate (160 mg three times
daily)/placebo (three times daily), prepared in an identical form,
for 12 weeks. This dose of ibuprofen has been shown previously to
down-regulate the acute phase response in gastrointestinal cancer
(McMillan et al, 1995; Preston et al, 1995; Wigmore et al, 1995).
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Patients did not have surgery, radiotherapy or chemotherapy in the
6 weeks before study or during the study period. Furthermore, no
patient received corticosteroids or non-steroidal anti-inflammatory
drugs other than ibuprofen during the course of the study.
The study was approved by the local hospital ethical commit-
tees and all patients were informed of the purpose and procedure
of the study and all gave written informed consent.
Total body water was measured using a Xitron 4000B bio-
impedance spectrum analyser (Xitron Technologies, San Diego,
CA, USA) as previously described (Haman et al, 1995).
To assess appetite, the patients were asked to describe their
appetite on a 10-cm linear analogue scale, ranging from poor
appetite to good appetite (Raben et al, 1995).
For skinfold anthropometry, measurements of biceps and triceps
skinfold thickness were undertaken using Harpenden skinfold
callipers (British Indicator, West Sussex, UK) and mid-upper arm
circumference using a stretch-resistant tape as described previ-
ously (Heymsfield et al, 1994). These measurements were carried
out because they have been reported to correlate directly with
weight change (Harries et al, 1985).
Circulating C-reactive protein and albumin concentrations were
measured using standard methods (McMillan et al, 1994c).
Karnofsky performance status: the functional ability of patients
was assessed using an 11-point numerical scale and a score was
given depending on the level of independence (Mor et al, 1984).
EuroQol-EQ-5D: general health state was assessed by the
patient defining which statement in each of five groups best
described their state of health. Also, a linear analogue scale was
marked by the patient to define their present level of health (The
EuroQol group, 1990).
EORTC QLQ-C30: different aspects of quality of life were
assessed using this cancer-specific 30-item questionnaire which
has six functional scales (physical, role, emotional, cognitive,
social, global health status) and several questions relating to range
of physical symptoms (Aaronson et al, 1993). Patients marked to
what extent each statement applied to them.
Statistics
Data are presented as median and range. When appropriate, differ-
ences between megestrol acetate/placebo and megestrol
acetate/ibuprofen group data were tested for statistical significance
using the Mann—Whitney U-test and Fisher￿s exact test. Data from
different time periods within each group were tested for statistical
significance using the Freidman test, and, when appropriate,
comparisons of data from different time periods were carried out
using the Wilcoxon signed rank test (Minitab; Minitab, State
College, PA, USA).
From our previous study of megestrol acetate alone (McMillan
et al, 1994a), the mean weight change at 6 weeks was —1.4 kg (s.d.
2.2 kg). In contrast, in the pilot study of megestrol acetate and
ibuprofen (McMillan et al, 1997), the mean weight change at
6 weeks was 2.2 kg (s.d. 2.9 kg). Based on a power of 80% to
detect a mean difference in weight change of 2.5 kg, at a 5%
significance level, assuming a s.d. within groups of 2.6 kg, there
was a minimum requirement of 19 evaluable patients in each
group at 6 weeks.
RESULTS
Seventy-three patients were included in the study. Of these, 38 and
35 were randomized to the megesterol acetate/placebo and meges-
terol acetate/ibuprofen groups respectively. Thirty-two patients
failed to reach the 4—6 week assessment, mainly because of
disease progression requiring hospital admission, and a further 14
patients failed to reach 12 weeks.
The baseline characteristics of the patients at study entry are
given in Tables 1 and 2. Overall, the median weight loss of the
patients entered into the study was 18%. Moreover, the patients￿
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Table 1 Baseline characteristics of weight-losing gastrointestinal cancer patients
Megestrol acetate Megestrol acetate P-value
and placebo and ibuprofen
(n = 38) (n = 35)
Sex (F/M) 17/21 13/22 NS
Age (years)a 72 (50–90) 69 (52–88) NS
Body mass indexa 18.7 (12.0–27.7) 20.6 (14.8–26.9) NS
Weight loss (%)a 18 (5–33) 18 (5–34) NS
Appetite score (scale 0–10)a 3.0 (0.0–10.0) 4.0 (0.3–9.1) NS
Biceps skinfold thickness (mm)a 4.4 (1.8–13.0) 4.8 (2.0–13.0) NS
Triceps skinfold thickness (mm)a 7.5 (2.0–23.2) 8.0 (3.0–15.7) NS
Mid-upper arm circumference (cm)a 23.7 (16.0–30.2) 24.1 (17.5–29.1) NS
Total body water (l)a 28.0 (18.7–45.3) 29.5 (21.4–37.1) NS
Albumin (g l–1)a 35 (20–46) 35 (28–50) NS
C-reactive protein (mg l–1)a 29 (<6–160) 24 (<6–253) NS
Cancer site
Colorectal (n)3 4 N S
Oesophageal (n)2 2 N S
Gastric (n)6 5 N S
Pancreatic (n)2 5 2 4 N S
Cholangiocarcinoma (n)1 0 N S
aValues are median (range).median appetite score, using the linear analogue scale, was low
(between 3 and 4). Both groups were similar except for the nausea
and vomiting score of the EORTC QLQ-C30 questionnaire, which
was higher in the group who received megestrol acetate/placebo.
Of the 41 patients who were assessed at 4—6 weeks, there was a
significant decrease in the circulating concentrations of C-reactive
protein, in those patients with detectable concentrations
(>5 mg l—1), in the megestrol acetate/ibuprofen group (n = 10,
P < 0.05), but not in the megestrol acetate/placebo group (n = 13,
P = 0.21). Of the ten patients who had detectable C-reactive
protein concentrations and were given megestrol acetate and
ibuprofen, after 4—6 weeks eight patients had a decrease, one
patient had no change and one patient had an increase in circu-
lating C-reactive protein concentrations. This was associated with
an increase in appetite score in eight out of ten patients.
Compared with baseline values, there was a significant increase
in the linear analogue appetite scores (Table 3) in both treatment
groups (P < 0.05). Despite this general improvement in appetite,
median weight continued to decrease (—1.5 kg) and there was a
significant decrease in the mid-upper arm circumference (—0.6 cm,
P < 0.05) in the megestrol acetate/placebo group. In contrast, there
were significant increases in the median weight (1.0 kg, P < 0.05)
and total body water (median 1.31, P < 0.05) in those receiving
megestrol acetate/ibuprofen.
There was a significant increase in weight and mid-upper arm
circumference in the megestrol acetate/ibuprofen group compared
with the respective values in the megesterol acetate/placebo group
after 4—6 weeks treatment (Table 3, Figure 1, P < 0.01). On an inten-
tion-to-treat basis, at the 4—6 week assessment 2 of the 38 patients in
the megestrol acetate/placebo group gained at least 2 kg in weight
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Table 2 Baseline quality of life of weight-losing gastrointestinal cancer patients
Megestrol acetate Megestrol acetate P-value
and placebo and ibuprofen
(n = 38) (n = 35)
Median (range) Median (range)
KPSa 60 (50–90) 60 (50–90) NS
EuroQol-EQ-5D 0.630 (–0.095–1.000) 0.689 (–0.261–1.000) NS
EORTC QLQ-C30
Physical functioning 50 (0–100) 60 (0–100) NS
Role functioning 83.3 (66.7–100) 83.3 (66.7–100) NS
Emotional functioning 66.7 (0–100) 75.0 (25.0–100) NS
Cognitive functioning 66.7 (0–100) 83.3 (0–100) NS
Social functioning 66.7 (0–100) 66.7 (0–100) NS
Quality of life 33.3 (0–91.7) 33.3 (0–83.3) NS
Fatigue 55.5 (0–100) 50.0 (11.1–100) NS
Nausea and vomiting 33.3 (0–100) 0 (0–100) <0.05
Pain 33.3 (0–83.3) 33.3 (0–83.3) NS
Dyspnoea 0 (0–100) 0 (0–100) NS
Sleep disturbance 33.3 (0–100) 33.3 (0–100) NS
Appetite loss 66.7 (0–100) 66.7 (0–100) NS
Constipation 0 (0–100) 0 (0–100) NS
Diarrhoea 0 (0–100) 0 (0–100) NS
Financial difficulty 0 (0–100) 0 (0–100) NS
aKarnofsky performance status.
Table 3 Change in patient characteristics and anthropometry over initial 4–6 weeks
Megestrol acetate Megestrol acetate P-value
and placebo and ibuprofen
(n = 19) (n = 22)
Median (range) Median (range)
Change in appetite score 3.0 (–2.0–9)* 2.0 (–5.0–8.9)* NS
Weight gain (kg) –1.5 (–6.0–4.5) 1.0 (–3.7–6.5)* <0.01
Change in biceps skinfold thickness 0 (–2.4–2.0) 0 (–3.7–0.9) NS
(mm)
Change in triceps skinfold thickness –0.1 (–5.0–2.6) 0 (–2.8–1.7) NS
(mm)
Change in mid-upper arm –0.6 (–5.7–0.6)* 0.1 (–2.5–3.1) <0.01
circumference (cm)
Change in albumin (g l–1 1 (–6–6) –1 (–6–6) NS
*P < 0.05 compared with baseline values.compared with 8 of the 35 patients in the megestrol acetate/ibuprofen
group (P = 0.063). There was no significant change in total body
water between the two groups.
Compared with baseline values, at 4—6 weeks there was a signif-
icant increase in the EORTC QLQ-C30 appetite scores in both
treatment groups (P < 0.05). However, comparing the two groups,
there were no differences in any of the quality of life parameters
measured.
After 12 weeks, compared with baseline values, there was a
significant decrease in median body weight (—2.8 kg) in the mege-
strol acetate/placebo group and an increase (2.3 kg) in the mege-
strol acetate/ibuprofen group (Table 4, P < 0.05). These changes
were accompanied by a significant decrease in the mid-upper arm
circumference of the megestrol acetate/placebo group (P < 0.05).
After 12 weeks of treatment, there was a significant difference
between the median weight gain in the megesterol acetate/ibuprofen
group compared with median weight loss in the megestrol
acetate/placebo group (Table 4, Figure 2, P < 0.001). On an
intention-to-treat basis, at the 12-week assessment only 1 of the 38
patients in the megestrol acetate/placebo group gained at least 2 kg
in weight compared with 9 of the 35 patients in the megestrol
acetate/ibuprofen group (P < 0.01). At 12 weeks, there were
insufficient total body water observations to permit meaningful
statistical analysis of body composition.
Comparing the two groups at 12 weeks, there was a significant
improvement in the EuroQol-EQ-5D quality of life score of the
megesterol acetate/ibuprofen group (P < 0.05).
During the study, venous thrombosis was recorded in three
patients (one receiving megestrol acetate/placebo and two receiving
megestrol acetate/ibuprofen) and upper gastrointestinal bleeding
was recorded in three patients (one, fatal, receiving megestrol
acetate/placebo and two receiving megestrol acetate/ibuprofen). All
of these patients had locally invasive pancreatic cancer and were
treated conservatively. There were clinically detectable ascites in
five patients, two receiving megestrol acetate/placebo and three
receiving megestrol acetate/ibuprofen. Only three patients, one in
the megestrol acetate/placebo group and two in the megestrol
acetate/ibuprofen group, were available for assessment at 12 weeks.
No weight correction for such ascites was carried out. There was no
clinically apparent congestive heart failure or deterioration in
glucose tolerance observed in any of the patients studied. Failure of
patients to reach assessment points (other than those detailed above)
was due to disease progression resulting in changes in supportive
care/pain control.
498 DC McMillan et al
British Journal of Cancer (1999) 79(3/4), 495–500 © Cancer Research Campaign 1999
Table 4 Change in patient characteristics and anthropometry over 12 weeks
Megestrol acetate Megestrol acetate P-value
and placebo and ibuprofen
(n = 11) (n = 16)
Median (range) Median (range)
Change in appetite score 1.0 (–3.0–9.2) 1.0 (–5.0–8.1) NS
Weight gain (kg) –2.8 (–7.0–2.2)* 2.3 (–2.0–12.4)* <0.001
Change in biceps skinfold thickness –0.5 (–3.3–0) –0.2 (–4.4–3.0) NS
(mm)
Change in triceps skinfold thickness 0 (–4.8–1.8) 0.1 (–0.6–6.0)* NS
(mm)
Change in mid-upper arm –1.0 (–5.7–0.4)* 0 (–5.4–3.0) <0.05
circumference (cm)
Change in albumin (g l–1 0 (–8–3) –2 (–5–1)* NS





























































Figure 1 Weight change after 6 weeks in gastrointestinal cancer patients
randomized to receive treatment with megestrol acetate/placebo (n = 19) or
megestrol acetate/ibuprofen (n = 22) combination
Figure 2 Weight change after 12 weeks in gastrointestinal cancer patients
randomized to receive treatment with megestrol acetate/ placebo (n = 11) or
megestrol acetate/ibuprofen (n = 16) combinationDISCUSSION
We have previously reported that the presence of an inflammatory
response (as documented by an elevated C-reactive protein) is
associated with increased weight loss in cancer patients (Scott et
al, 1996; McMillan et al, 1997). In the present study, ibuprofen
was given to attenuate the inflammatory response, mediated in part
by proinflammatory cytokines such as interleukin 6 and the corti-
costeroids such as cortisol (McMillan et al, 1995), and as a conse-
quence normalize host metabolism (Preston et al, 1995; Wigmore
et al, 1995). The results of the present study are consistent with the
anti-inflammatory effects of ibuprofen because there was a signif-
icant reduction in circulating C-reactive protein concentrations of
those patients with a detectable acute phase protein response in the
megestrol acetate/ibuprofen group.
In the present study, the megestrol acetate/placebo group lost
weight at both 4—6 weeks (median 1.5 kg) and 12 weeks (median
2.8 kg) assessments. In contrast, the administration of megestrol
acetate/ibuprofen was associated with weight gain after 4—6 weeks
(median 1.0 kg) and 12 weeks (median 2.3 kg). The amount of
weight lost in the megestrol acetate alone group and the amount of
weight gained in the megestrol acetate/ibuprofen group was
similar to our previous studies in weight-losing gastrointestinal
cancer patients (McMillan et al, 1994a, 1997).
At 12 weeks, in the megestrol acetate/ibuprofen treatment group,
circulating albumin concentrations were decreased compared with
baseline values. In some circumstances, this may be consistent with
fluid retention. However, such concentrations in cancer patients are
dependent on a number of other factors (Fearon et al, 1998).
To examine the nature of the changes in body weight, total body
water volumes were measured in the majority of patients at the 4—6
week assessment. There was a significant increase in total body
water in the megestrol acetate/ibuprofen treatment group compared
with baseline. This occurred in the absence of clinically detectable
oedema in the majority of the patients, thereby suggesting that at
least a proportion of the weight gained was lean body mass. In this
study, despite measuring total body water, we were unable to deter-
mine unequivocally the nature of the weight gained.
There have been few studies which have examined the relation-
ship between weight loss, performance status and quality of life in
cancer patients. Ovesen and colleagues (1993) have reported that, in
a mixed cohort of patients with lung, breast and ovarian cancer,
weight loss is associated with reduced performance status and lower
quality of life scores. Therefore, it is of interest that in the present
study an increase in weight in the megestrol acetate/ibuprofen group
was associated with an improvement in quality of life when
compared with the megestrol acetate/placebo group.
Studies of palliative treatment in advanced cancer patients are
fraught with difficulties in terms of analysis and interpretation of
clinical relevance. Firstly, the attrition rate in such studies is high
(63% at 12 weeks in the present study), and this contributes to a
constantly changing patient population. Secondly, there is a need in
such studies to examine changes from baseline which are clinically
relevant. One approach to address these problems is to analyse the
results on an intention-to-treat basis and examine the proportion of
the cohort who had gained benefit. In the present study, our main
finding was an increase in body weight in the megestrol acetate/
ibuprofen group. Previous reports have suggested that a clinically
relevant increase in weight would be approximately 2 kg (Loprinzi
et al, 1990; Feliu et al, 1991; Tchemedyian et al, 1992). We have,
therefore, analysed the results of the present study taking the above
factors into account. At 12 weeks, significantly more patients in the
megestrol acetate/ibuprofen group gained at least 2 kg in weight.
This would suggest that these findings are of clinical significance.
Although these results demonstrate that weight gain can be
achieved by the combination of megestrol acetate plus ibuprofen,
we cannot exclude the possibility that ibuprofen alone would have
been as effective.
The results of the present study suggest that weight loss in
gastrointestinal cancer patients can be reversed using the combina-
tion of megestrol acetate and ibuprofen. Furthermore, this weight
gain may be associated with an improvement in quality of life. The
nature of the weight gain and whether maintaining or increasing
weight improves the survival of such cachectic patients remains to
be determined. Nevertheless, this non-toxic regimen may be of
therapeutic benefit in other cancers in which weight loss is associ-
ated with the presence of an inflammatory response.
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